ACUT
Price
$0.90
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
14.47M
ONWRF
Price
$5.45
Change
+$0.21 (+4.01%)
Updated
Jul 2 closing price
Capitalization
240.95M
Interact to see
Advertisement

ACUT vs ONWRF

Header iconACUT vs ONWRF Comparison
Open Charts ACUT vs ONWRFBanner chart's image
Accustem Sciences
Price$0.90
Change-$0.00 (-0.00%)
Volume$37.67K
Capitalization14.47M
Onward Med
Price$5.45
Change+$0.21 (+4.01%)
Volume$1.86K
Capitalization240.95M
ACUT vs ONWRF Comparison Chart in %
Loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONWRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. ONWRF commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and ONWRF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (ACUT: $0.90 vs. ONWRF: $5.45)
Brand notoriety: ACUT and ONWRF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 932% vs. ONWRF: 159%
Market capitalization -- ACUT: $14.47M vs. ONWRF: $240.95M
ACUT [@Biotechnology] is valued at $14.47M. ONWRF’s [@Biotechnology] market capitalization is $240.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileONWRF’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • ONWRF’s FA Score: 0 green, 5 red.
According to our system of comparison, ACUT is a better buy in the long-term than ONWRF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACUT’s TA Score shows that 4 TA indicator(s) are bullish while ONWRF’s TA Score has 5 bullish TA indicator(s).

  • ACUT’s TA Score: 4 bullish, 4 bearish.
  • ONWRF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ACUT is a better buy in the short-term than ONWRF.

Price Growth

ACUT (@Biotechnology) experienced а +1.58% price change this week, while ONWRF (@Biotechnology) price change was +19.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.52%. For the same industry, the average monthly price growth was +13.89%, and the average quarterly price growth was -0.53%.

Industries' Descriptions

@Biotechnology (+5.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ONWRF($241M) has a higher market cap than ACUT($14.5M). ACUT YTD gains are higher at: 100.893 vs. ONWRF (-9.147).
ACUTONWRFACUT / ONWRF
Capitalization14.5M241M6%
EBITDA-1.42MN/A-
Gain YTD100.893-9.147-1,103%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash36.4KN/A-
Total Debt57.6KN/A-
TECHNICAL ANALYSIS
Technical Analysis
ACUTONWRF
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
66%
Bearish Trend 5 days ago
60%
Momentum
ODDS (%)
Bearish Trend 5 days ago
85%
Bullish Trend 5 days ago
33%
MACD
ODDS (%)
Bearish Trend 5 days ago
80%
Bullish Trend 5 days ago
31%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
33%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
41%
Advances
ODDS (%)
N/A
Bullish Trend 6 days ago
50%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
50%
Aroon
ODDS (%)
Bullish Trend 5 days ago
90%
Bearish Trend 5 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONWRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRGAX39.660.34
+0.86%
iShares Russell 1000 Large-Cap Idx Inv A
MMSCX10.820.07
+0.65%
Praxis Small Cap Index A
JFACX37.780.21
+0.56%
JHancock Fundamental All Cap Core R2
VADRX75.400.37
+0.49%
Invesco Equally-Wtd S&P 500 R
RYHCX85.760.11
+0.13%
Rydex Health Care C

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and LGVN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and LGVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
N/A
LGVN - ACUT
30%
Poorly correlated
+0.77%
OKYO - ACUT
28%
Poorly correlated
-4.47%
IGMS - ACUT
21%
Poorly correlated
+3.03%
APVO - ACUT
20%
Poorly correlated
N/A
VRNA - ACUT
20%
Poorly correlated
+1.61%
More

ONWRF and

Correlation & Price change

A.I.dvisor tells us that ONWRF and MRVI have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ONWRF and MRVI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ONWRF
1D Price
Change %
ONWRF100%
N/A
MRVI - ONWRF
30%
Poorly correlated
+0.75%
VIR - ONWRF
30%
Poorly correlated
-0.37%
AGIO - ONWRF
23%
Poorly correlated
+2.04%
ACUT - ONWRF
9%
Poorly correlated
N/A
HLVX - ONWRF
3%
Poorly correlated
N/A
More